Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04930445 · ClinicalTrials.gov registry record
Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD
A clinical trial, sponsored by Pfizer.
- Terminated
- Registry status
- 265
- Enrollment target
NCT04930445 is a clinical trial that was terminated before completion, run by Pfizer. The registered enrollment target is 265 participants.
The verdict
NCT04930445 was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- 265 participants
- Enrollment target
Study Summary
This registry is an observational study designed to evaluate the effect of Oxbryta in individuals with SCD in a real-world setting.
Interventions
- DRUG Oxbryta® (voxelotor) 500mg Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2022-02-04 |
| Est. Completion | 2024-10-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04930445
The ClinicalTrials.gov registry entry for NCT04930445 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxbryta® (voxelotor) 500mg Tablets is the first listed.
NCT04930445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04930445 about?
NCT04930445 is a clinical study titled "Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD". This registry is an observational study designed to evaluate the effect of Oxbryta in individuals with SCD in a real-world setting.
What is the current status of trial NCT04930445?
This trial is currently terminated. The enrollment target is 265 participants. The study started on 2022-02-04. Estimated completion is 2024-10-10.
What interventions are being tested in trial NCT04930445?
The interventions under investigation include: Oxbryta® (voxelotor) 500mg Tablets (DRUG).
Who is sponsoring clinical trial NCT04930445?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.